Literature DB >> 6580858

Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome.

C K Yeung, K L Wong, W L Ng.   

Abstract

The effectiveness of intravenous methylprednisolone pulses in 20 mg/kg/day for three consecutive days was compared with a more conventional oral prednisone regime in inducing remission in adult patients presenting with first episodes of minimal change nephrotic syndrome. Methylprednisolone was significantly less effective and failed to induce remission in six of nine patients within two weeks of treatment, while the oral prednisone regime was uniformly effective in all eight patients within five weeks. Of the six non-responders to methylprednisolone five subsequently remitted with oral prednisone, and one with cyclophosphamide. Except for one patient in the oral prednisone group who had acute gastritis with bleeding, no serious side-effect was seen with either treatment regimes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580858     DOI: 10.1111/j.1445-5994.1983.tb04479.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  8 in total

Review 1.  [Minimal change disease and focal segmental glomerulosclerosis].

Authors:  J Müller-Deile; H Schenk; M Schiffer
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

2.  High dose methylprednisolone therapy in nephrotic syndrome.

Authors:  H Mocan; E Erduran; G Karagüzel
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

3.  Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.

Authors:  Ryohei Yamamoto; Enyu Imai; Shoichi Maruyama; Hitoshi Yokoyama; Hitoshi Sugiyama; Kosaku Nitta; Tatsuo Tsukamoto; Shunya Uchida; Asami Takeda; Toshinobu Sato; Takashi Wada; Hiroki Hayashi; Yasuhiro Akai; Megumu Fukunaga; Kazuhiko Tsuruya; Kosuke Masutani; Tsuneo Konta; Tatsuya Shoji; Takeyuki Hiramatsu; Shunsuke Goto; Hirofumi Tamai; Saori Nishio; Arimasa Shirasaki; Kojiro Nagai; Kunihiro Yamagata; Hajime Hasegawa; Hidemo Yasuda; Shizunori Ichida; Tomohiko Naruse; Kei Fukami; Tomoya Nishino; Hiroshi Sobajima; Satoshi Tanaka; Toshiyuki Akahori; Takafumi Ito; Terada Yoshio; Ritsuko Katafuchi; Shouichi Fujimoto; Hirokazu Okada; Eiji Ishimura; Junichiro James Kazama; Keiju Hiromura; Tetsushi Mimura; Satashi Suzuki; Yosuke Saka; Tadashi Sofue; Yusuke Suzuki; Yugo Shibagaki; Kiyoki Kitagawa; Kunio Morozumi; Yoshiro Fujita; Makoto Mizutani; Takashi Shigematsu; Naoki Kashihara; Hiroshi Sato; Seiichi Matsuo; Ichiei Narita; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2018-04-20       Impact factor: 2.801

Review 4.  Interventions for minimal change disease in adults with nephrotic syndrome.

Authors:  Karolis Azukaitis; Suetonia C Palmer; Giovanni Fm Strippoli; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2022-03-01

Review 5.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

6.  Predictors of Relapse in Adult-Onset Nephrotic Minimal Change Disease.

Authors:  Hajeong Lee; Kyung Don Yoo; Yun Kyu Oh; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Curie Ahn; Jin Suk Han; Chun Soo Lim
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 7.  Interventions for minimal change disease in adults with nephrotic syndrome.

Authors:  S C Palmer; K Nand; G F Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

8.  Seasonal relapsing minimal change disease: a novel strategy for avoiding long-term immunosuppression.

Authors:  Christopher Lawrence; H Terry Cook; Liz Lightstone
Journal:  Case Rep Nephrol Urol       Date:  2012-07-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.